However, another FGF19 variant NGM282 (M70) retains the beneficial BA metabolism effects, while is devoid of murine mitogenic activity by inactivating the STAT3 pathway.695 To date, M70 as one FGF19 variant was studied through phase II clinical trials for their use in patients with primary sclerosing cholangitis and diabetes mellitus. This evidence concerns the gene FGF19 and sclerosing cholangitis.